DYN Dyne Therapeutics Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: DYN

Price (delayed)

$22.72

Market cap

$3.76B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$3.19

Enterprise value

$3.18B

?
Relative Growth: Rel. Growth: 11
Relative Strength: Rel. Strength: 88
Relative Valuation: Rel. Valuation: N/A
Relative Profitability: Rel. Profitability: 4

Dyne Therapeutics, Inc. operates as a biotechnology company. The Company focuses on transforming the lives of people with serious diseases by developing muscle-targeted therapies. Dyne Therapeutics offers its services in ...

Highlights
DYN's EPS is up by 11% year-on-year and by 8% since the previous quarter
The equity has grown by 29% YoY but it has contracted by 11% from the previous quarter
DYN's net income is down by 23% YoY
Dyne Therapeutics's quick ratio has decreased by 14% from the previous quarter and by 5% YoY
Sector: Healthcare
Industry: Biotechnology
Website: http://www.dyne-tx.com
Peers: NRG AES CNP

Key stats

What are the main financial stats of DYN

DYN stock price

How has the Dyne Therapeutics stock price performed over time
Intraday
-5.29%
1 week
-6.39%
1 month
25.73%
1 year
143.52%
YTD
16.16%
QTD
2.3%

Financial performance

How have Dyne Therapeutics's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$471.09M
Net income
-$451.71M
Gross margin
N/A
Net margin
N/A
DYN's net income is down by 23% YoY
DYN's operating income is down by 19% YoY

Price vs fundamentals

How does DYN's price correlate with its fundamentals

Growth

What is Dyne Therapeutics's growth rate over time

Valuation

What is Dyne Therapeutics stock price valuation
P/E
N/A
P/B
4.33
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
DYN's EPS is up by 11% year-on-year and by 8% since the previous quarter
The price to book (P/B) is 70% higher than the last 4 quarters average of 2.7 and 43% higher than the 5-year quarterly average of 3.2
The equity has grown by 29% YoY but it has contracted by 11% from the previous quarter

Efficiency

How efficient is Dyne Therapeutics business performance
DYN's return on invested capital is up by 30% year-on-year and by 14% since the previous quarter
The return on equity has declined by 10% year-on-year but it is up by 5% since the previous quarter
The company's return on assets rose by 8% QoQ and by 4.1% YoY

Dividends

What is DYN's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for DYN.

Financial health

How did Dyne Therapeutics financials performed over time
The company's total assets rose by 50% YoY but it fell by 9% QoQ
Dyne Therapeutics's quick ratio has decreased by 14% from the previous quarter and by 5% YoY
The debt is 80% smaller than the equity
The equity has grown by 29% YoY but it has contracted by 11% from the previous quarter
Dyne Therapeutics's debt to equity has increased by 18% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.